Regeneron Pharmaceuticals (REGN) Times Interest Earned (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Times Interest Earned of $24.64 for Q2 2026, down 76.72% year-over-year from $105.83 in Q2 2025, and up 8.46% quarter-over-quarter from $22.72 in Q1 2026.
Powered by 
Analysis
Regeneron Pharmaceuticals (REGN) Times Interest Earned (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Times Interest Earned history runs 18 years deep, the most recent figure standing at $24.64 for Q2 2026.
- In Q2 2026, Times Interest Earned fell 76.72% year-over-year to $24.64; the TTM figure through Jun 2026 stood at $73.2 (down 80.56% YoY), while the FY2025 annual figure was $28.85, up 359.41% from the prior year.
- Times Interest Earned for Q2 2026 stood at $24.64, up from $22.72 in the prior quarter.
- The five-year high for Times Interest Earned was $125.34 in Q4 2024, with the low at $3.53 in Q3 2022.
- The 5-year median for Times Interest Earned is $23.68 (2026), against an average of $36.8.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned plunged 98.31% in 2022, then surged 814.66% in 2024.
- Regeneron Pharmaceuticals' Times Interest Earned stood at $65.91 in 2022, then dropped by 19.77% to $52.88 in 2023, then soared by 137.05% to $125.34 in 2024, then declined by 29.8% to $87.99 in 2025, then slumped by 72.0% to $24.64 in 2026.
- Business Quant data shows REGN's Times Interest Earned at $24.64 in Q2 2026, $22.72 in Q1 2026, and $87.99 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 1,199.14 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 117.59 |
| Mar 31, 2026 | 49.84 |
| Dec 31, 2025 | 72.12 |
| Sep 30, 2025 | 53.20 |
| Jun 30, 2025 | 299.86 |
| Mar 31, 2025 | 68.01 |
| Dec 31, 2024 | 94.30 |
| Sep 30, 2024 | 85.47 |
| Jun 30, 2024 | 72.27 |
| Mar 31, 2024 | 46.67 |
| Dec 31, 2023 | 53.16 |
| Sep 30, 2023 | 62.42 |
| Jun 30, 2023 | 53.78 |
| Mar 31, 2023 | 52.59 |
| Dec 31, 2022 | 65.91 |
| Sep 30, 2022 | 79.98 |
| Jun 30, 2022 | 84.73 |
| Mar 31, 2022 | 92.54 |
| Dec 31, 2021 | 187.21 |
| Sep 30, 2021 | 130.08 |